Atossa Genetics (NASDAQ:ATOS) Share Price Passes Below Two Hundred Day Moving Average – Here’s Why

Atossa Genetics Inc. (NASDAQ:ATOS) shares crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $6.42 and traded as low as $1.81. Atossa Genetics shares last traded at $1.83, with a volume of 466,738 shares trading hands.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ATOS. Weiss Ratings lowered shares of Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. Ascendiant Capital Markets reduced their price target on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating for the company in a report on Friday, April 10th. Finally, HC Wainwright raised their price target on shares of Atossa Genetics to $25.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Two analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Atossa Genetics has an average rating of “Hold” and an average price target of $24.50.

Atossa Genetics Price Performance

The firm has a market capitalization of $15.76 million, a price-to-earnings ratio of -0.57 and a beta of 1.24. The business has a 50 day moving average of $4.74 and a 200 day moving average of $6.42.

Atossa Genetics (NASDAQ:ATOS) last posted its quarterly earnings results on Friday, May 8th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.12). On average, sell-side analysts forecast that Atossa Genetics Inc. will post -4.3 EPS for the current fiscal year.

Institutional Trading of Atossa Genetics

Several institutional investors have recently made changes to their positions in ATOS. Vanguard Group Inc. increased its stake in Atossa Genetics by 4.2% in the third quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock valued at $5,270,000 after acquiring an additional 245,717 shares during the period. Ameriprise Financial Inc. acquired a new stake in Atossa Genetics during the second quarter valued at approximately $2,468,000. Renaissance Technologies LLC boosted its holdings in Atossa Genetics by 33.2% during the fourth quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock valued at $1,217,000 after purchasing an additional 514,175 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Atossa Genetics by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 1,371,909 shares of the company’s stock valued at $810,000 after purchasing an additional 9,627 shares during the period. Finally, State Street Corp raised its holdings in shares of Atossa Genetics by 31.2% in the 4th quarter. State Street Corp now owns 596,485 shares of the company’s stock worth $352,000 after buying an additional 141,990 shares in the last quarter. 12.74% of the stock is currently owned by institutional investors and hedge funds.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.